| scholarly article | Q13442814 |
| P50 | author | Bo Ahrén | Q5544506 |
| P2860 | cites work | Mechanisms of action of glucagon-like peptide 1 in the pancreas | Q24683764 |
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties | Q33237060 | ||
| Emerging treatment options for type 2 diabetes | Q34381281 | ||
| Alpha cell function in health and disease: influence of glucagon-like peptide-1. | Q34560507 | ||
| Association of pancreatitis with glucagon-like peptide-1 agonist use. | Q34618507 | ||
| Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial | Q34745045 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| The role of GLP-1 in the life and death of pancreatic beta cells. | Q36012488 | ||
| Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin | Q36812821 | ||
| Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing | Q37364896 | ||
| Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? | Q37395298 | ||
| Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes | Q37483511 | ||
| Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes | Q37641377 | ||
| Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes | Q37767054 | ||
| Pharmacokinetics of dipeptidylpeptidase-4 inhibitors | Q37768821 | ||
| Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin | Q37857686 | ||
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks | Q40718093 | ||
| One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice | Q42991300 | ||
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial | Q43086322 | ||
| Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes | Q43274458 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes | Q43972608 | ||
| Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia | Q45032390 | ||
| Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes | Q45250947 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes | Q46143605 | ||
| Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia | Q46691047 | ||
| Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus | Q47333601 | ||
| Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes | Q83292729 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1239-1245 | |
| P577 | publication date | 2011-01-13 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Experimental Cell Research | Q1524289 |
| P1476 | title | GLP-1 for type 2 diabetes | |
| P478 | volume | 317 |
| Q92684616 | A novel inducible acute hyperglycemia mouse model for assessing 6-KTP |
| Q51327644 | Assessment of beta-cell function in young patients with type 2 diabetes: arginine-stimulated insulin secretion may reflect beta-cell reserve |
| Q26827955 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes |
| Q37670181 | Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass |
| Q27028127 | DPP-4 inhibition and islet function |
| Q35996636 | Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis |
| Q40803621 | Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis |
| Q37929744 | Emerging GLP-1 receptor agonists |
| Q38436840 | Experimental and clinical aspects of melatonin and clock genes in diabetes |
| Q38243035 | Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective |
| Q34265490 | Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis |
| Q38104126 | Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives |
| Q42495476 | Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell |
| Q36820392 | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon |
| Q91012235 | Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV |
| Q48837078 | Neuroprotective Effects of rhGLP-1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury |
| Q40572806 | Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations |
| Q27023585 | Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? |
| Q35594860 | Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice |
| Q49385666 | PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells. |
| Q99545741 | Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes |
| Q35895868 | Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control |
| Q33630394 | The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. |
| Q83540652 | The Dynamic Incretin Adaptation and Type 2 Diabetes |
| Q37913528 | The future of incretin‐based therapy: novel avenues—novel targets |
| Q37939244 | The structure and function of the glucagon-like peptide-1 receptor and its ligands |
| Q39169322 | Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents |
| Q26824702 | Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales |
| Q36905790 | Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. |
| Q36924521 | Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion |
| Q37910976 | Using albumin to improve the therapeutic properties of diabetes treatments |
Search more.